Therapeutic effect of lymphokine-activated killer cells treated with low-dose ionizing radiation on osteosarcoma

被引:3
作者
Zhao, Lei [1 ]
Lv, Ming [2 ]
Sayimu, Wuliya [3 ]
Liu, Wei [4 ]
Zhang, Huawu [1 ]
Jiang, Bo [1 ]
Wang, Dong [1 ]
机构
[1] Shandong Univ, Dept Orthoped, Prov Hosp Affiliated, Jinan 250021, Shandong, Peoples R China
[2] Zibo Cent Hosp, Dept Orthoped, Zibo 255012, Shandong, Peoples R China
[3] Xinjiang Uygur Autonomous Reg Ctr Dis Control, Urumqi 830011, Xinjiang, Peoples R China
[4] Shandong Acad Med Sci, Inst Radiat Med, Jinan 250062, Shandong, Peoples R China
关键词
low-dose ionizing; lymphokine-activated killer cells; osteosarcoma; proliferation; antitumor; OF-THE-ART; STEM-CELL; INTERLEUKIN-2; CANCER; APOPTOSIS; PATHWAYS; ALPHA;
D O I
10.3892/ol.2015.3271
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present study was to investigate the effect of lymphokine-activated killer (LAK) cells, which received low-dose ionizing radiation, on the treatment of osteosarcoma in rats. The cultured UMR-106 cells were inoculated under the anterior chest skin of 24 rats to establish an osteosarcoma model. In addition, the LAK cells from 24 mice were exposed to doses of 0 (control group), 0.65 or 3.25 mGy X-ray radiation. The tritiated thymidine (H-3-TdR) release method and Winn assay were performed to determine the antitumor effects of the LAK cells. The proliferation of the mouse LAK cells treated with 3.25 mGy radiation was significantly higher than that for those treated with 0 or 0.65 mGy radiation, which suggested that low-dose ionizing radiation stimulates the proliferation of LAK cells. The tumor-bearing rats were divided into three groups and injected with LAK cells that had already received 0, 0.65 or 3.25 mGy radiation. The mean survival time of the 3.25-mGy group was longer than that of the 0- and 0.65-mGy groups. After 30 days, tumors with weights of similar to 6.25 and 2.0 g were identified in the rats of the 0- and 0.65-mGy groups, respectively. However, tumor proliferation was not detectable in the rats of the 3.25-mGy radiation group. Therefore, low-dose ionizing radiation effectively kills osteosarcoma cells in rats by stimulating the proliferation and enhancing the cytotoxicity of LAK cells.
引用
收藏
页码:879 / 882
页数:4
相关论文
共 28 条
[1]  
Ai Jinxia, 2010, ZHONG GUO MIAN YI XU, V26, P26
[2]   Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways [J].
Balasa, Balaji ;
Yun, Rui ;
Belmar, Nicole A. ;
Fox, Melvin ;
Chao, Debra T. ;
Robbins, Michael D. ;
Starling, Gary C. ;
Rice, Audie G. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (01) :61-73
[3]   INTRATUMORAL LAK CELL AND INTERLEUKIN-2 THERAPY OF HUMAN GLIOMAS [J].
BARBA, D ;
SARIS, SC ;
HOLDER, C ;
ROSENBERG, SA ;
OLDFIELD, EH .
JOURNAL OF NEUROSURGERY, 1989, 70 (02) :175-182
[4]  
Fu Q, 1995, CHINESE J RADIOLOGIC, V15, P321
[5]   Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines [J].
Fujii, Hiromasa ;
Honoki, Kanya ;
Tsujiuchi, Toshifumi ;
Kido, Akira ;
Yoshitani, Kazuhiro ;
Takakura, Yoshinori .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 34 (05) :1381-1386
[6]   Cancer stem cells Seeds of growth in osteosarcoma [J].
Gillette, Jennifer M. ;
Nielsen-Preiss, Sheila M. .
CANCER BIOLOGY & THERAPY, 2009, 8 (06) :553-554
[7]   Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target [J].
Herrero-Martin, D. ;
Osuna, D. ;
Ordonez, J. L. ;
Sevillano, V. ;
Martins, A. S. ;
Mackintosh, C. ;
Campos, M. ;
Madoz-Gurpide, J. ;
Otero-Motta, A. P. ;
Caballero, G. ;
Amaral, A. T. ;
Wai, D. H. ;
Braun, Y. ;
Eisenacher, M. ;
Schaefer, K-L ;
Poremba, C. ;
de Alava, E. .
BRITISH JOURNAL OF CANCER, 2009, 101 (01) :80-90
[8]  
Heymann Dominique, 2013, Bonekey Rep, V2, P378, DOI 10.1038/bonekey.2013.112
[9]   Extraskeletal Osteosarcoma: A case report and review of the literature [J].
Hoch, Michael ;
Ali, Sayed ;
Agrawal, Shefali ;
Wang, Congli ;
Khurana, Jasvir S. .
JOURNAL OF RADIOLOGY CASE REPORTS, 2013, 7 (07) :15-23
[10]   Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites [J].
Jennings, V. A. ;
Ilett, E. J. ;
Scott, K. J. ;
West, E. J. ;
Vile, R. ;
Pandha, H. ;
Harrington, K. ;
Young, A. ;
Hall, G. D. ;
Coffey, M. ;
Selby, P. ;
Errington-Mais, F. ;
Melcher, A. A. .
INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (05) :1091-1101